Screening for PINK1 mutations in patients with early- and late-onset Parkinson's Disease

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

PINK1 MUTATIONS AND THE RISK OF PARKINSON'S DISEASE IN FAMILY MEMBERS OF SOUTHERN ITALY

MYOCARDIAL 123I-METAIODOBENZYLGUANIDINE UPTAKE IN GENETIC PARKINSON’S DISEASE.

PINK mutation and the risk of parkinson's disease in family members of southern Italy

Gender-related effect of clinical and genetic variables on the cognitive impairment in MS.